Atypical and anaplastic meningiomas treated with bevacizumab.
about
Medical management of brain tumors and the sequelae of treatment.Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.Prognostic factors for patients with World Health Organization grade III meningiomas treated at a single centerIntratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomasDouble-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma.Antiangiogenic agents for nonmalignant brain tumors.Medical management of meningiomas.RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.Assessment of Brain Tumor Response: RANO and Its Offspring.Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas.Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution.World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment.A five year-old child with clear cell petro-clival meningioma: case report with clinical and histopathological long-term follow-up.Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningioma.Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptakeMeningioma.LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.Survival benefit of postoperative radiation in papillary meningioma: Analysis of the National Cancer Data Base.Pathogenesis of peri-tumoral edema in intracranial meningiomas.Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma.Effect of boron neutron capture therapy for recurrent anaplastic meningioma: an autopsy case report.Systemic therapy for recurrent meningioma.Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.Endothelial Cell Hypertrophy and Microvascular Proliferation in Meningiomas Are Correlated with Higher Histological Grade and Shorter Progression-Free Survival.Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.[Chemotherapy of brain tumors in aduts].Antiangiogenic Treatment of MeningiomasEmerging Medical Treatments for Meningioma in the Molecular Era
P2860
Q26992174-51671AD9-A904-45E2-9A81-A35F93990A58Q30361848-2EBF6775-7E77-4B12-88DC-561288506892Q30393860-6CE18891-ED1B-4235-94BD-62EBD3301FC6Q30455709-9A9FCE67-8686-41E4-A426-E5A22F3D6214Q33433136-CC940B45-4B09-4D48-8A20-85DCF8FF264CQ33879903-7A5E5D52-4C4F-4DC5-8C24-8EC6A035D858Q35903183-6F06E281-5A55-4EC9-A6D7-6A237587F982Q36346636-B4B39B6B-EA3E-4F09-826E-A3D55B3BC495Q36618245-206C0268-E04B-442D-BBB7-B24BAF8160E6Q36943867-BFB6DC5E-E423-4DA1-8E0F-1FC2C961A6D5Q37007819-032CFED4-8927-40D2-B33F-56A4A41603F6Q38233448-62B0C12E-185B-4C83-891C-8DEED08F8F50Q38782798-0F4C6D83-5E99-402E-B68B-B0F543165358Q38855020-F0543BAC-6A66-41EA-98C2-37212FD5B5B7Q38979594-00CBADDC-CC15-46EC-BDB6-DA9012D6B886Q39172845-7CBD5C29-87D5-449F-B438-F9750253C0EAQ40812108-D1C08763-58E1-4CFD-AD2D-C901605F8E3EQ40832763-917FD6B1-66D3-4A18-8EAA-89C334F68223Q42396777-DC0E9F0B-EA7B-48F9-AE8A-D0CCA789D42CQ42702315-4F6448AA-F24E-4F21-8665-984F3B85F568Q44118008-6B8BF8DA-2954-4D6B-A262-7829961B6980Q45074588-031B1C9E-371F-42AD-99D4-1A48260BCB8AQ47621240-7F550822-E80D-4F98-8395-2BFC5E9D15F8Q48140644-7062F070-6D7C-4EFD-B112-A2B8A066FC08Q48249218-C28F1B5F-22AA-4647-BE37-5CEBC32F8E2CQ48787127-5581E806-1410-4655-A817-1C0CE8E5E647Q48787594-19CC4CA2-2713-48CE-A8B1-E3D6AB2C32B9Q51288413-F286FB20-CEC0-43E9-9C0A-65C2EF33FAC1Q51734097-170892DA-D243-49EA-8FAC-AD8DBF98C360Q53246945-9CA63D3D-F838-4D71-AEE9-B33152B7F741Q54383059-5DE257FA-CC6A-4DB7-8C51-5C0FC99620FAQ55460138-B4F5AA03-4031-4842-9F6A-C3D480CC791FQ58002991-29BDEF89-CA81-469C-9742-70D7303E3445Q58798211-7B7BA966-52FC-4064-80F6-FD81E26586C1
P2860
Atypical and anaplastic meningiomas treated with bevacizumab.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Atypical and anaplastic meningiomas treated with bevacizumab.
@en
type
label
Atypical and anaplastic meningiomas treated with bevacizumab.
@en
prefLabel
Atypical and anaplastic meningiomas treated with bevacizumab.
@en
P2093
P2860
P1476
Atypical and anaplastic meningiomas treated with bevacizumab
@en
P2093
Andrew D Norden
Eudocia Quant Lee
Fabio M Iwamoto
Jan Drappatz
Jeremy D Rudnick
Lakshmi Nayak
P2860
P2888
P304
P356
10.1007/S11060-012-0886-4
P577
2012-04-29T00:00:00Z
P6179
1041832990